A Phase I study of the safety, pharmacokinetics and efficacy of navitoclax plus docetaxel in patients with advanced solid tumors
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
A Phase I study of the safety, pharmacokinetics and efficacy of navitoclax plus docetaxel in patients with advanced solid tumors
Authors
Keywords
-
Journal
Future Oncology
Volume -, Issue -, Pages -
Publisher
Future Medicine Ltd
Online
2021-04-14
DOI
10.2217/fon-2021-0140
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Allosteric modulation of sigma receptors by BH3 mimetics ABT-737, ABT-263 (Navitoclax) and ABT-199 (Venetoclax)
- (2019) John R. Lever et al. PHARMACOLOGICAL RESEARCH
- Targeting prosurvival BCL2 signaling through Akt blockade sensitizes castration‐resistant prostate cancer cells to enzalutamide
- (2019) Amanda B. Pilling et al. PROSTATE
- Mutant p53 drives cancer chemotherapy resistance due to loss of function on activating transcription of PUMA
- (2019) Yuan Huang et al. CELL CYCLE
- Differential mRNA expression of the main apoptotic proteins in normal and malignant cells and its relation to in vitro resistance
- (2018) Andrea Vazanova et al. Cancer Cell International
- BCL-2 as therapeutic target for hematological malignancies
- (2018) Guilherme Fleury Perini et al. Journal of Hematology & Oncology
- Targeting BCL-2 regulated apoptosis in cancer
- (2018) Kirsteen J. Campbell et al. Open Biology
- Role of the tumor microenvironment in regulating apoptosis and cancer progression
- (2016) Katherine Yaacoub et al. CANCER LETTERS
- Antagonism of Bcl-XL is necessary for synergy between carboplatin and BH3 mimetics in ovarian cancer cells
- (2016) Mohammed Najim Abed et al. Journal of Ovarian Research
- Phase 1 study of the safety, pharmacokinetics, and antitumour activity of the BCL2 inhibitor navitoclax in combination with rituximab in patients with relapsed or refractory CD20+lymphoid malignancies
- (2015) Andrew W. Roberts et al. BRITISH JOURNAL OF HAEMATOLOGY
- Safety, efficacy, and pharmacokinetics of navitoclax (ABT-263) in combination with erlotinib in patients with advanced solid tumors
- (2015) Anthony W. Tolcher et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Safety, efficacy, and pharmacokinetics of navitoclax (ABT-263) in combination with irinotecan: results of an open-label, phase 1 study
- (2015) Anthony W. Tolcher et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- A phase 2 study of the BH3 mimetic BCL2 inhibitor navitoclax (ABT-263) with or without rituximab, in previously untreated B-cell chronic lymphocytic leukemia
- (2015) Thomas J. Kipps et al. LEUKEMIA & LYMPHOMA
- Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy
- (2015) Joel D. Leverson et al. Science Translational Medicine
- Broad targeting of resistance to apoptosis in cancer
- (2015) Ramzi M. Mohammad et al. SEMINARS IN CANCER BIOLOGY
- Potent and selective small-molecule MCL-1 inhibitors demonstrate on-target cancer cell killing activity as single agents and in combination with ABT-263 (navitoclax)
- (2015) J D Leverson et al. Cell Death & Disease
- A phase I clinical trial of navitoclax, a targeted high-affinity Bcl-2 family inhibitor, in combination with gemcitabine in patients with solid tumors
- (2014) James M. Cleary et al. INVESTIGATIONAL NEW DRUGS
- A phase I safety and pharmacokinetic study of ABT-263 in combination with carboplatin/paclitaxel in the treatment of patients with solid tumors
- (2014) Gordana Vlahovic et al. INVESTIGATIONAL NEW DRUGS
- ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
- (2013) Andrew J Souers et al. NATURE MEDICINE
- Bcl-2, Bcl-xL, and Bcl-w are not equivalent targets of ABT-737 and navitoclax (ABT-263) in lymphoid and leukemic cells
- (2012) D. Merino et al. BLOOD
- Phase II Study of Single-Agent Navitoclax (ABT-263) and Biomarker Correlates in Patients with Relapsed Small Cell Lung Cancer
- (2012) C. M. Rudin et al. CLINICAL CANCER RESEARCH
- Targeting the B-Cell Lymphoma/Leukemia 2 Family in Cancer
- (2012) Matthew S. Davids et al. JOURNAL OF CLINICAL ONCOLOGY
- Navitoclax (ABT-263) Reduces Bcl-xL-Mediated Chemoresistance in Ovarian Cancer Models
- (2012) M. Wong et al. MOLECULAR CANCER THERAPEUTICS
- Phase I Study of Navitoclax (ABT-263), a Novel Bcl-2 Family Inhibitor, in Patients With Small-Cell Lung Cancer and Other Solid Tumors
- (2011) Leena Gandhi et al. JOURNAL OF CLINICAL ONCOLOGY
- Substantial Susceptibility of Chronic Lymphocytic Leukemia to BCL2 Inhibition: Results of a Phase I Study of Navitoclax in Patients With Relapsed or Refractory Disease
- (2011) Andrew W. Roberts et al. JOURNAL OF CLINICAL ONCOLOGY
- The Bcl-2/Bcl-XL/Bcl-w Inhibitor, Navitoclax, Enhances the Activity of Chemotherapeutic Agents In Vitro and In Vivo
- (2011) J. Chen et al. MOLECULAR CANCER THERAPEUTICS
- The Bcl-2 inhibitor ABT-263 enhances the response of multiple chemotherapeutic regimens in hematologic tumors in vivo
- (2010) Scott Ackler et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity
- (2010) Wyndham H Wilson et al. LANCET ONCOLOGY
- ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor
- (2008) C. Tse et al. CANCER RESEARCH
- Therapeutic Efficacy of ABT-737, a Selective Inhibitor of BCL-2, in Small Cell Lung Cancer
- (2008) C. L. Hann et al. CANCER RESEARCH
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started